InvestorsHub Logo
Followers 39
Posts 2870
Boards Moderated 0
Alias Born 12/06/2003

Re: None

Monday, 03/05/2018 11:16:24 PM

Monday, March 05, 2018 11:16:24 PM

Post# of 1721
The witch hunters are at the height of dudgeon in their efforts to destroy one of the least offensive purveyors of the drug best suited to alleviate the dying agonies of the doomed.

I have seen no data on how many patients given prescriptions for Subsys for extreme pain might not be in pain or if they are in great pain have gotten hooked before dying thus endangering their immortal souls for all eternity but Allison Prang of the Wall Street Journal [or only a published guest] seems in a mad rush to do in INSY, perhaps so the screams of the damned dying in agony will fill the Heavenly Father with joy that sinners are being saved and will be quickly admitted to Heaven.

Maybe there is some other motive for always skipping details but I have never ever seen any journalists begging forgiveness for their carelessness.

Some short sellers say analysts aren't doing their homework. To critics, the company's drug pipeline isn't that attractive, and the company could end up owing more than what it's set aside for litigation costs. As of March 2, 16.9% of shares outstanding were being sold short, according to data from S&P Capital IQ.

"These people are complete imbeciles," Marc Cohodes, a former Insys short seller, said of the analysts.


https://www.advfn.com/news_Opioid-Maker-Insys-Still-Has-Fans-on-Wall-Street_76869729.html

Perhaps those analysts and this uncompensated, unconnected, unknown, small shareholder are all idiots but I hate to see people and animals suffer. I can't speak for Whoever Might Be Over Us All because I am uninformed on such matters.

Suffering I know a lot about as a very old Vietnam veteran and INSY stockholder.

Mob - Many heads, no brains - Benjamin Franklin

Best, Terry

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.